前立腺肥大症治療薬市場：治療薬クラス（αブロッカー、5-αリダクターゼ阻害剤、ホスホジエステラーゼ-5阻害剤、その他）、治療タイプ（単剤療法、併用療法）別。世界の機会分析および産業予測、2021-2030年

Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class (Alpha Blocker, 5-Alpha Reductase Inhibitor, Phosphodiesterase-5 Inhibitor, and Others) and Therapy Type (Mono Drug Therapy and Combination Drug Therapy): Global Opportunity Analysis and Industry Forecast, 2021–2030

世界の前立腺肥大症治療薬市場は、2020年には56億9770万ドルとなり、2021年から2030年までの年平均成長率は5.00%で、2030年には93億9150万ドルに達すると予測されています。前立腺は、男性の生殖器系において尿... もっと見る

出版社	出版年月	電子版価格	ページ数	言語
Allied Market Research アライドマーケットリサーチ	2022年1月25日	US$6,168 シングルユーザーライセンスライセンス・価格情報・注文方法はこちら	216	英語

サマリー

世界の前立腺肥大症治療薬市場は、2020年には56億9770万ドルとなり、2021年から2030年までの年平均成長率は5.00%で、2030年には93億9150万ドルに達すると予測されています。
前立腺は、男性の生殖器系において尿道を取り囲むクルミ大の腺です。この腺の主な機能は、液体を分泌し、他の腺からの液体や睾丸からの精子細胞と混ざって精液を生成することです。前立腺肥大症（BPH）は、前立腺の大きさが増加する非悪性腫瘍です。前立腺肥大症、前立腺肥大症とも呼ばれます。男性は年をとるにつれて、前立腺は大きく2つの成長段階を経ます。1つ目は、思春期を通じて前立腺の大きさが2倍になるときです。第二の成長段階は、25歳から始まり、男性の一生の間続きます。前立腺肥大症は、この第二の成長期によく見られます。
前立腺が大きくなると、尿道を圧迫して挟み込みます。膀胱の内壁が厚くなる。膀胱から尿が自由に流れなくなり、夜間排尿、尿意逡巡、排尿困難、尿の流れが弱い、または流れが止まったり始まったりする、排尿の最後に垂れる、尿意切迫感などの症状が出ます。膀胱を完全に空にする力が時間とともに弱まり、膀胱に尿が残ってしまう尿閉になることもあります。前立腺肥大症の症状の多くは、尿道の狭窄と尿閉、つまり膀胱を完全に空にすることができないことによって起こります。尿漏れや夜間頻尿などの症状があるため、前立腺肥大症は患者さんのQOL（生活の質）に大きな影響を及ぼします。また、治療せずに長期間放置すると、膀胱損傷、膀胱結石、腎臓損傷、尿路感染症など、より深刻な健康問題を引き起こすことになります。さらに、下部尿路症状（LUTS）は、高齢になるにつれて男女ともに一般的になってきています。LUTSは、男性の前立腺肥大症（BPH）と関連していることが多いのです。
この疾患は一般的に50歳以上の男性に発症するため、男性老年人口が増加することがこの市場の主な要因となっています。例えば、The Administration for Community Livingによると、Administration on Agingを含む、米国保健社会福祉省の運営部門である。2019年、アメリカの65歳以上の人口は5410万人で、そのうち男性は約2410万人でした。65歳以上の人口全体は、2009年の3960万人から2019年には5410万人と36％増加し、2060年には9470万人に達すると予測されています。2040年には高齢者人口は約8,080万人となり、2000年の2倍以上となる。このように、特に男性における高齢者人口の増加が、市場の成長を牽引することが予想されます。また、The Official Foundation of the American Urological Associationによると、51歳から60歳の男性の約半数、80歳以上の男性の約90％がBPHであるといわれています。
その他、人口の不健康なライフスタイルの増加、泌尿器科疾患に対する意識の高まり、病状の早期診断、前立腺がんの増加、世界の前立腺肥大症患者数の増加などが、市場の成長を後押ししています。また、勃起不全の家族歴、肥満、2型糖尿病、運動不足、勃起不全などは、いずれも前立腺肥大症のリスクファクターとされています。治療薬としては、αブロッカー、5αリダクターゼ阻害剤、ホスホジエステラーゼ-5阻害剤などが主に使用されています。さらに、抗ムスカリン薬、抗コリン薬、β3アドレナリン受容体薬も使用されています。
しかし、腹腔鏡下前立腺切除術、経尿道的針療法（TUNA）、経尿道的マイクロ波温熱療法（TUMT）といった低侵襲手術への嗜好は、世界のBPH治療薬市場の成長を妨げています。さらに、パイプラインに多数の製品が存在することや、未開拓の新興国における高い市場ポテンシャルは、予測期間中に魅力的な機会として機能すると予想されます。
世界の前立腺肥大症治療薬市場は、治療クラス、治療法、地域に基づいて区分されます。治療薬クラスでは、市場はαブロッカー、5α還元酵素阻害剤、ホスホジエステラーゼ-5阻害剤、その他に分類されます。治療法別では、単剤療法と併用療法に市場を二分しています。地域別では、北米、欧州、アジア太平洋、中南米中東アフリカ（LAMEA）に分けて分析しています。
本レポートで紹介する主要企業は、Abbott Laboratories、AbbVie (Allergan Plc)、Astellas Pharma Inc.、Boehringer Ingelheim Pharma GmbH & Co.KG、Eli Lilly and Company、GlaxoSmithKline plc.、Merck & Co.(Merck Sharp & Dohme Corp.)、Pfizer Inc.、SanofiおよびTeva Pharmaceutical Industries Limited。

ステークホルダーにとっての主なメリット
- 本レポートでは、世界の前立腺肥大症治療薬市場における現在および新興の市場動向とダイナミクスを幅広く分析し、有力な機会を特定します。
- 本調査では、世界市場の競争環境を提示し、地域ごとの競争環境を予測します。
- 市場の成長を促進および制限する要因の包括的な分析を提供しています。
- 市場動向とダイナミクスを理解するために、地域別・国別の分析が提供されています。

主要な市場セグメント
#治療薬クラス別
## アルファブロッカー
## 5-αリダクターゼ阻害剤
## ホスホジエステラーゼ5阻害剤
##その他

#治療法別
## 単剤療法
## 併用療法

#地域別
##北アメリカ
###米国
###カナダ
###メキシコ
##ヨーロッパ
###イギリス
###ドイツ
###フランス
###スペイン
###イタリア
###その他のヨーロッパ
##アジア太平洋
###中国
###日本
###インド
###オーストラリア
###韓国
###その他のアジア太平洋地域
#ラメア
###ブラジル
###南アフリカ
###サウジアラビア
### LAMEAの残りの地域

# 主要な市場関係者

## Abbott Laboratories
## AbbVie (Allergan Plc)
#アステラス製薬株式会社
# ベーリンガーインゲルハイムファーマGmbH & Co.KG
#イーライリリー・アンド・カンパニー
#グラクソ・スミスクライン plc.
## Merck & Co.(メルク・シャープ・アンド・ドーム社)
#ファイザー株式会社
# サノフィ
## テバ・ファーマシューティカル・インダストリーズ・リミテッド

ページTOPに戻る

CHAPTER 1:INTRODUCTION

1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments

1.3.1.List of key players profile in the report

1.4.Research methodology

1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

2.1.Key findings of the study
2.2.CXO perspective

CHAPTER 3:MARKET LANDSCAPE

3.1.Market definition and scope
3.2.Key findings

3.2.1.Top investment pockets

3.3.Porter’s five forces analysis
3.4.Top player positioning, 2020
3.5.Market dynamics

3.5.1.Drivers

3.5.1.1.Rise in geriatric population
3.5.1.2.Surge in prevalence of benign prostatic hyperplasia
3.5.1.3.Increase in awareness toward urological disorders
3.5.1.4.Surge in healthcare expenditure worldwide

3.5.2.Restraint

3.5.2.1.High preference for minimally invasive surgical therapies

3.5.3.Opportunities

3.5.3.1.Large number of products in pipeline
3.5.3.2.Lucrative opportunities in emerging markets

3.6.Impact analysis
3.7.Impact analysis of COVID-19 on the benign prostatic hyperplasia therapeutics market
3.8.Clinical trials analysis, 2019-2022

CHAPTER 4:BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPEUTIC CLASS

4.1.Overview

4.1.1.Market size and forecast

4.2.Alpha blockers

4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast, by region
4.2.3.Market analysis, by country
4.3.5- alpha reductase inhibitors
4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast, by region
4.3.3.Market analysis, by country

4.4.Phosphodiesterase-5 inhibitors

4.4.1.Key market trends, growth factors, and opportunities
4.4.2.Market size and forecast, by region
4.4.3.Market analysis, by country

4.5.Others

4.5.1.Key market trends, growth factors, and opportunities
4.5.2.Market size and forecast, by region
4.5.3.Market analysis, by country

CHAPTER 5:BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPY

5.1.Overview

5.1.1.Market size and forecast

5.2.Mono drug therapy

5.2.1.Market size and forecast, by region
5.2.2.Market analysis, by country

5.3.Combination drug therapy

5.3.1.Market size and forecast, by region
5.3.2.Market analysis, by country

CHAPTER 6:BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY REGION

6.1.Overview

6.1.1.Market size and forecast

6.2.North America

6.2.1.Key market trends, growth factors, and opportunities
6.2.2.North America benign prostatic hyperplasia therapeutics market, by therapeutic class
6.2.3.North America benign prostatic hyperplasia therapeutics market, by therapy
6.2.4.Market size and forecast, by country

6.2.4.1.U.S.

6.2.4.1.1.U.S. benign prostatic hyperplasia therapeutics market, by therapeutic class
6.2.4.1.2.U.S. benign prostatic hyperplasia therapeutics market, by therapy

6.2.4.2.Canada

6.2.4.2.1.Canada benign prostatic hyperplasia therapeutics market, by therapeutic class
6.2.4.2.2.Canada benign prostatic hyperplasia therapeutics market, by therapy

6.2.4.3.Mexico

6.2.4.3.1.Mexico benign prostatic hyperplasia therapeutics market, by therapeutic class
6.2.4.3.2.Mexico benign prostatic hyperplasia therapeutics market, by therapy

6.3.Europe

6.3.1.Key market trends, growth factors, and opportunities
6.3.2.Europe benign prostatic hyperplasia therapeutics market, by therapeutic class
6.3.3.Europe benign prostatic hyperplasia therapeutics market, by therapy
6.3.4.Market size and forecast, by country

6.3.4.1.Germany

6.3.4.1.1.Germany benign prostatic hyperplasia therapeutics market, by therapeutic class
6.3.4.1.2.Germany benign prostatic hyperplasia therapeutics market, by therapy

6.3.4.2.France

6.3.4.2.1.France benign prostatic hyperplasia therapeutics market, by therapeutic class
6.3.4.2.2.France benign prostatic hyperplasia therapeutics market, by therapy

6.3.4.3.UK

6.3.4.3.1.UK benign prostatic hyperplasia therapeutics market, by therapeutic class
6.3.4.3.2.UK benign prostatic hyperplasia therapeutics market, by therapy

6.3.4.4.Italy

6.3.4.4.1.Italy benign prostatic hyperplasia therapeutics market, by therapeutic class
6.3.4.4.2.Italy benign prostatic hyperplasia therapeutics market, by therapy

6.3.4.5.Spain

6.3.4.5.1.Spain benign prostatic hyperplasia therapeutics market, by therapeutic class
6.3.4.5.2.Spain benign prostatic hyperplasia therapeutics market, by therapy

6.3.4.6.Rest of Europe

6.3.4.6.1.Rest of Europe benign prostatic hyperplasia therapeutics market, by therapeutic class
6.3.4.6.2.Rest of Europe benign prostatic hyperplasia therapeutics market, by therapy

6.4.Asia-Pacific

6.4.1.Key market trends, growth factors, and opportunities
6.4.2.Asia-Pacific benign prostatic hyperplasia therapeutics market, by therapeutic class
6.4.3.Asia-Pacific benign prostatic hyperplasia therapeutics market, by therapy
6.4.4.Market size and forecast, by country

6.4.4.1.Japan

6.4.4.1.1.Japan benign prostatic hyperplasia therapeutics market, by therapeutic class
6.4.4.1.2.Japan benign prostatic hyperplasia therapeutics market, by therapy

6.4.4.2.China

6.4.4.2.1.China benign prostatic hyperplasia therapeutics market, by therapeutic class
6.4.4.2.2.China benign prostatic hyperplasia therapeutics market, by therapy

6.4.4.3.Australia

6.4.4.3.1.Australia benign prostatic hyperplasia therapeutics market, by therapeutic class
6.4.4.3.2.Australia benign prostatic hyperplasia therapeutics market, by therapy

6.4.4.4.India

6.4.4.4.1.India benign prostatic hyperplasia therapeutics market, by therapeutic class
6.4.4.4.2.India benign prostatic hyperplasia therapeutics market, by therapy

6.4.4.5.South Korea

6.4.4.5.1.South Korea benign prostatic hyperplasia therapeutics market, by therapeutic class
6.4.4.5.2.South Korea benign prostatic hyperplasia therapeutics market, by therapy

6.4.4.6.Rest of Asia-Pacific

6.4.4.6.1.Rest of Asia-Pacific benign prostatic hyperplasia therapeutics market, by therapeutic class
6.4.4.6.2.Rest of Asia-Pacific benign prostatic hyperplasia therapeutics market, by therapy

6.5.LAMEA

6.5.1.Key market trends, growth factors, and opportunities
6.5.2.LAMEA benign prostatic hyperplasia therapeutics market, by therapeutic class
6.5.3.LAMEA benign prostatic hyperplasia therapeutics market, by therapy
6.5.4.LAMEA benign prostatic hyperplasia therapeutics market, by country

6.5.4.1.Brazil

6.5.4.1.1.Brazil benign prostatic hyperplasia therapeutics market, by therapeutic class
6.5.4.1.2.Brazil benign prostatic hyperplasia therapeutics market, by therapy

6.5.4.2.Saudi Arabia

6.5.4.2.1.Saudi Arabia benign prostatic hyperplasia therapeutics market, by therapeutic class
6.5.4.2.2.Saudi Arabia benign prostatic hyperplasia therapeutics market, by therapy

6.5.4.3.South Africa

6.5.4.3.1.South Africa benign prostatic hyperplasia therapeutics market, by therapeutic class
6.5.4.3.2.South Africa benign prostatic hyperplasia therapeutics market, by therapy

6.5.4.4.Rest of LAMEA

6.5.4.4.1.Rest of LAMEA benign prostatic hyperplasia therapeutics market, by therapeutic class
6.5.4.4.2.Rest of LAMEA benign prostatic hyperplasia therapeutics market, by therapy

CHAPTER 7:COMPANY PROFILES

7.1.ABBOTT LABORATORIES

7.1.1.Company overview
7.1.2.Company snapshot
7.1.3.Operating business segments
7.1.4.Product portfolio
7.1.5.Business performance

7.2.ABBVIE INC. (ALLERGAN INC.)

7.2.1.Company overview
7.2.2.Company snapshot
7.2.3.Operating business segments
7.2.4.Product portfolio
7.2.5.Business performance

7.3.ASTELLAS PHARMA INC.

7.3.1.Company overview
7.3.2.Company snapshot
7.3.3.Operating business segments
7.3.4.Product portfolio
7.3.5.Business performance

7.4.BOEHRINGER INGELHEIM INTERNATIONAL GMBH

7.4.1.Company overview
7.4.2.Company snapshot
7.4.3.Operating business segments
7.4.4.Product portfolio
7.4.5.Business performance

7.5.ELI LILLY AND COMPANY

7.5.1.Company overview
7.5.2.Company snapshot
7.5.3.Operating business segments
7.5.4.Product portfolio
7.5.5.Business performance

7.6.GLAXOSMITHKLINE PLC.

7.6.1.Company overview
7.6.2.Company snapshot
7.6.3.Operating business segments
7.6.4.Product portfolio
7.6.5.Business performance

7.7.MERCK & CO. INC. (MERCK SHARP & DOHME CORP.)

7.7.1.Company overview
7.7.2.Company snapshot
7.7.3.Operating business segments
7.7.4.Product portfolio
7.7.5.Business performance

7.8.PFIZER INC.

7.8.1.Company overview
7.8.2.Company snapshot
7.8.3.Operating business segments
7.8.4.Product portfolio
7.8.5.Business performance

7.9.SANOFI

7.9.1.Company overview
7.9.2.Company snapshot
7.9.3.Operating business segments
7.9.4.Product portfolio
7.9.5.Business performance

7.10.TEVA PHARMACEUTICAL INDUSTRIES LTD.

7.10.1.Company overview
7.10.2.Company snapshot
7.10.3.Operating business segments
7.10.4.Product portfolio
7.10.5.Business performance
7.10.6.Key strategic moves and developments

List of Tables

LIST OF TABLES

TABLE 01.BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY CLINICAL TRIALS
TABLE 02.BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPEUTIC CLASS, 2020–2030 ($MILLION)
TABLE 03.ALPHA BLOCKERS MARKET, BY REGION, 2021-2030 ($MILLION)
TABLE 04.5- ALPHA REDUCTASE INHIBITORS MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 05.PHOSPHODIESTERASE-5 INHIBITORS MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 06.OTHERS MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 07.BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPY, 2020–2030 ($MILLION)
TABLE 08.MONO DRUG THERAPY, BY REGION, 2020–2030 ($MILLION)
TABLE 09.COMBINATION DRUG THERAPY, BY REGION, 2020–2030($MILLION)
TABLE 10.BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 11.NORTH AMERICA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPEUTIC CLASS, 2020-2030 ($MILLION)
TABLE 12.NORTH AMERICA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPY, 2020-2030 ($MILLION)
TABLE 13.NORTH AMERICA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 14.U.S. BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPEUTIC CLASS, 2020-2030 ($MILLION)
TABLE 15.U.S. BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPY, 2020-2030 ($MILLION)
TABLE 16.CANADA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPEUTIC CLASS, 2020-2030 ($MILLION)
TABLE 17.CANADA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPY, 2020-2030 ($MILLION)
TABLE 18.MEXICO BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPEUTIC CLASS, 2020-2030 ($MILLION)
TABLE 19.MEXICO BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPY, 2020-2030 ($MILLION)
TABLE 20.EUROPE BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPEUTIC CLASS, 2020-2030 ($MILLION)
TABLE 21.EUROPE BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPY, 2020-2030 ($MILLION)
TABLE 22.EUROPE BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 23.GERMANY BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPEUTIC CLASS, 2020-2030 ($MILLION)
TABLE 24.GERMANY BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPY, 2020-2030 ($MILLION)
TABLE 25.FRANCE BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPEUTIC CLASS, 2020-2030 ($MILLION)
TABLE 26.FRANCE BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPY, 2020-2030 ($MILLION)
TABLE 27.UK BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPEUTIC CLASS, 2020-2030 ($MILLION)
TABLE 28.UK BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPY, 2020-2030 ($MILLION)
TABLE 29.ITALY BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPEUTIC CLASS, 2020-2030 ($MILLION)
TABLE 30.ITALY BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPY, 2020-2030 ($MILLION)
TABLE 31.SPAIN BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPEUTIC CLASS, 2020-2030 ($MILLION)
TABLE 32.SPAIN BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPY, 2020-2030 ($MILLION)
TABLE 33.REST OF EUROPE BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPEUTIC CLASS, 2020-2030 ($MILLION)
TABLE 34.REST OF EUROPE BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPY, 2020-2030 ($MILLION)
TABLE 35.ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPEUTIC CLASS, 2020-2030 ($MILLION)
TABLE 36.ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPY, 2020-2030 ($MILLION)
TABLE 37.ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 38.JAPAN BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPEUTIC CLASS, 2020-2030 ($MILLION)
TABLE 39.JAPAN BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPY, 2020-2030 ($MILLION)
TABLE 40.CHINA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPEUTIC CLASS, 2020-2030 ($MILLION)
TABLE 41.CHINA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPY, 2020-2030 ($MILLION)
TABLE 42.AUSTRALIA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPEUTIC CLASS, 2020-2030 ($MILLION)
TABLE 43.AUSTRALIA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPY, 2020-2030 ($MILLION)
TABLE 44.INDIA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPEUTIC CLASS, 2020-2030 ($MILLION)
TABLE 45.INDIA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPY, 2020-2030 ($MILLION)
TABLE 46.SOUTH KOREA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPEUTIC CLASS, 2020-2030 ($MILLION)
TABLE 47.SOUTH KOREA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPY, 2020-2030 ($MILLION)
TABLE 48.REST OF ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPEUTIC CLASS, 2020-2030 ($MILLION)
TABLE 49.REST OF ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPY, 2020-2030 ($MILLION)
TABLE 50.LAMEA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPEUTIC CLASS, 2020-2030 ($MILLION)
TABLE 51.LAMEA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPY, 2020-2030 ($MILLION)
TABLE 52.LAMEA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 53.BRAZIL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPEUTIC CLASS, 2020-2030 ($MILLION)
TABLE 54.BRAZIL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPY, 2020-2030 ($MILLION)
TABLE 55.SAUDI ARABIA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPEUTIC CLASS, 2020-2030 ($MILLION)
TABLE 56.SAUDI ARABIA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPY, 2020-2030 ($MILLION)
TABLE 57.SOUTH AFRICA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPEUTIC CLASS, 2020-2030 ($MILLION)
TABLE 58.SAUDI ARABIA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPY, 2020-2030 ($MILLION)
TABLE 59.REST OF LAMEA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPEUTIC CLASS, 2020-2030 ($MILLION)
TABLE 60.REST OF LAMEA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPY, 2020-2030 ($MILLION)
TABLE 61.ABBOTT: COMPANY SNAPSHOT
TABLE 62.ABBOTT: OPERATING SEGMENTS
TABLE 63.ABBOTT: PRODUCT PORTFOLIO
TABLE 64.ABBVIE: COMPANY SNAPSHOT
TABLE 65.ABBVIE: PRODUCT SEGMENT
TABLE 66.ABBVIE: PRODUCT PORTFOLIO
TABLE 67.ASTELLAS: COMPANY SNAPSHOT
TABLE 68.ASTELLAS: OPERATING SEGMENTS
TABLE 69.ASTELLAS: PRODUCT PORTFOLIO
TABLE 70.BOEHRINGER INGELHEIM: COMPANY SNAPSHOT
TABLE 71.BOEHRINGER INGELHEIM: OPERATING SEGMENTS
TABLE 72.BOEHRINGER INGELHEIM: PRODUCT PORTFOLIO
TABLE 73.LILLY: COMPANY SNAPSHOT
TABLE 74.LILLY: OPERATING SEGMENTS
TABLE 75.LILLY: PRODUCT PORTFOLIO
TABLE 76.GSK: COMPANY SNAPSHOT
TABLE 77.GSK: PRODUCT SEGMENTS
TABLE 78.GSK: PRODUCT PORTFOLIO
TABLE 79.MERCK: COMPANY SNAPSHOT
TABLE 80.MERCK: OPERATING SEGMENTS
TABLE 81.MERCK: PRODUCT PORTFOLIO
TABLE 82.PFIZER: COMPANY SNAPSHOT
TABLE 83.PFIZER: OPERATING BUSINESS SEGMENT
TABLE 84.PFIZER: PRODUCT PORTFOLIO
TABLE 85.SANOFI: COMPANY SNAPSHOT
TABLE 86.SANOFI: OPERATING SEGMENTS
TABLE 87.SANOFI: PRODUCT TYPE PORTFOLIO
TABLE 88.TEVA: COMPANY SNAPSHOT
TABLE 89.TEVA: OPERATING SEGMENTS
TABLE 90.TEVA: PRODUCT PORTFOLIO
TABLE 91.TEVA: KEY DEVELOPMENT

List of Figures

LIST OF FIGURES

FIGURE 01.GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SEGMENTATION
FIGURE 02.TOP INVESTMENT POCKETS
FIGURE 03.MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 04.MODERATE BARGAINING POWER OF BUYERS
FIGURE 05.MODERATE THREAT OF SUBSTITUTES
FIGURE 06.HIGH THREAT OF NEW ENTRANTS
FIGURE 07.MODERATE INTENSITY OF RIVALRY
FIGURE 08.TOP PLAYER POSITIONING, 2020
FIGURE 09.IMPACT ANALYSIS
FIGURE 10.COMPARATIVE ANALYSIS OF ALPHA BLOCKERS MARKET, BY COUNTRY, 2021-2030 (%)
FIGURE 11.COMPARATIVE ANALYSIS OF 5- ALPHA REDUCTASE INHIBITORS MARKET, BY COUNTRY, 2020-2030 (%)
FIGURE 12.COMPARATIVE ANALYSIS OF PHOSPHODIESTERASE-5 INHIBITORS MARKET, BY COUNTRY, 2020-2030 (%)
FIGURE 13.COMPARATIVE ANALYSIS OF OTHERS MARKET, BY COUNTRY, 2020-2030 (%)
FIGURE 14.COMPARATIVE ANALYSIS OF MONO DRUG THERAPY, BY COUNTRY, 2020-2030 (%)
FIGURE 15.COMPARATIVE ANALYSIS OF COMBINATION DRUG THERAPY, BY COUNTRY, 2020-2030 (%)
FIGURE 16.ABBOTT: NET SALES, 2018–2020 ($MILLION)
FIGURE 17.ABBOTT: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 18.ABBOTT: REVENUE SHARE BY REGION, 2020(%)
FIGURE 19.ABBVIE: NET SALES, 2018–2020 ($MILLION)
FIGURE 20.ABBVIE: REVENUE SHARE BY REGION, 2020(%)
FIGURE 21.ASTELLAS: NET SALES, 2018–2020 ($MILLION)
FIGURE 22.ASTELLAS: REVENUE SHARE, BY SEGMENTS, 2020 (%)
FIGURE 23.ASTELLAS: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 24.BOEHRINGER INGELHEIM: NET SALES, 2018–2020 ($MILLION)
FIGURE 25.BOEHRINGER INGELHEIM: REVENUE SHARE, BY SEGMENTS, 2020 (%)
FIGURE 26.BOEHRINGER INGELHEIM: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 27.LILLY: NET SALES, 2018–2020 ($MILLION)
FIGURE 28.LILLY: REVENUE SHARE BY REGION, 2020(%)
FIGURE 29.GSK: NET SALES, 2018–2020 ($MILLION)
FIGURE 30.GSK: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 31.GSK: REVENUE SHARE BY REGION, 2020(%)
FIGURE 32.MERCK: NET SALES, 2018–2020 ($MILLION)
FIGURE 33.MERCK: REVENUE SHARE, BY SEGMENTS, 2020 (%)
FIGURE 34.MERCK: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 35.PFIZER: NET SALES, 2018–2020 ($MILLION)
FIGURE 36.PFIZER: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 37.SANOFI: REVENUE, 2018–2020 ($MILLION)
FIGURE 38.SANOFI: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 39.SANOFI: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 40.TEVA: NET SALES, 2018–2020 ($MILLION)
FIGURE 41.TEVA: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 42.TEVA: REVENUE SHARE BY REGION, 2020(%)

ページTOPに戻る

Table of Contents

Summary

The global benign prostatic hyperplasia therapeutics market was valued at $5,697.70 million in 2020, and is estimated to reach $9,391.50 million by 2030, growing at a CAGR of 5.00% from 2021 to 2030.
The prostate is a walnut-sized gland that surrounds the urethra in the male reproductive system. The main function of this gland is to secrete a fluid, which mixes with the fluids from other glands and sperm cells from the testicles to generate semen. Benign prostatic hyperplasia (BPH) is a non-malignant increase in the size of the prostate gland. It is also called benign prostatic hypertrophy or benign prostatic obstruction. As a man gets older, his prostate goes through two major growth stages. The first happens when the prostate doubles in size throughout adolescence. The second stage of development begins at the age of 25 and lasts for the rest of a man's life. The BPH is common during the second growth phase.
As the prostate gland grows larger, it presses against and pinches the urethra. The bladder's lining thickens. It prevents urine from flowing freely from the bladder, resulting in nighttime urination, urinary hesitation, trouble starting to urinate, a weak urine stream or a stream that stops and begins, dribbling at the end of urination, and a sense of urgency to urinate. The bladder's ability to empty completely may weaken over time, causing urinary retention by leaving some urine in the bladder. Many of the symptoms of benign prostatic hyperplasia are caused by urethral constriction and urine retention, or the inability to empty the bladder entirely. Because of symptoms like urine leakage and nocturia, BPH has a substantial impact on the patient's quality of life. If untreated for a long duration, it results in more serious health issues, such as bladder damage, bladder stones, kidney damage, and urinary tract infections (UTIs). Moreover, lower urinary tract symptoms (LUTS) are becoming more common in both men and women as they get older. LUTS is frequently associated with benign prostatic hyperplasia in men (BPH).
This market is majorly driven by an increase in the male geriatric population because the disease generally occurs in men of age 50 and above. For instance, according to The Administration for Community Living, which includes the Administration on Aging, is an operating division of the U.S. Department of Health and Human Services. In 2019, the American population aged above 65 was 54.1 million among which about 24.1million were men. The overall population aged 65 and older increased from 39.6 million in 2009 to 54.1 million in 2019 a 36% increase and is projected to reach 94.7 million in 2060. By 2040, there will be about 80.8 million older persons, more than twice as many as in 2000. Thus, such increase in older population especially in males is anticipated to drive the growth of the market. In addition, according to The Official Foundation of the American Urological Association about half of all men aged between 51 and 60 years and up to 90% of men over age 80 have BPH.
The other factors boosting the market growth include increase in unhealthy lifestyle among the population, growth in awareness related to urological disorders, early diagnosis of the medical condition, rise in prostate cancer cases and rise in the number of global benign prostatic hyperplasia patients. In addition, a family history of erectile dysfunction, obesity, type 2 diabetes, insufficient exercise, and erectile dysfunction are all risk factors of BPH. The alpha blocker, 5-alpha reductase inhibitor, phosphodiesterase-5 inhibitor therapeutic class of drugs are the majorly used. Furthermore, antimuscarinics, anticholinergic agents, and beta 3 adrenoreceptor are also used.
However, preferences for minimally-invasive surgeries namely, laparoscopic prostatectomy, transurethral needle ablation (TUNA), and transurethral microwave thermotherapy (TUMT), hinder the growth of the global BPH therapeutics market. Furthermore, presence of a plethora of products in the pipeline and high market potential in untapped emerging economies are anticipated to serve as attractive opportunities during the forecast period.
The global benign prostatic hyperplasia therapeutics market is segmented on the basis of therapeutic class, therapy, and region. On the basis of therapeutic class, the market is categorized into alpha blocker, 5-alpha reductase inhibitor, phosphodiesterase-5 inhibitor, and others. By therapy, the market is bifurcated into mono drug therapy and combination drug therapy. Region-wise, it is analyzed across North America, Europe, Asia-Pacific, and Latin America Middle East and Africa (LAMEA).
The major players profiled in the report are Abbott Laboratories, AbbVie (Allergan Plc), Astellas Pharma Inc., Boehringer Ingelheim Pharma GmbH & Co. KG, Eli Lilly and Company, GlaxoSmithKline plc., Merck & Co., Inc. (Merck Sharp & Dohme Corp), Pfizer Inc., Sanofi and Teva Pharmaceutical Industries Limited.

KEY BENEFITS FOR STAKEHOLDERS
• This report provides an extensive analysis of the current and emerging market trends and dynamics in the global benign prostatic hyperplasia therapeutics market to identify the prevailing opportunities.
• This study presents the competitive landscape of the global market to predict the competitive environment across geographies.
• Comprehensive analysis of factors that drive and restrict the market growth is provided.
• Region- & country-wise analysis is provided to understand the market trends and dynamics.

KEY MARKET SEGMENTS
#By Therapeutics Class
## Alpha blockers
## 5- alpha reductase inhibitors
## Phosphodiesterase-5 inhibitors
##Others

#By Therapy
## Mono drug therapy
## Combination drug therapy

#By Region
##North America
###U.S.
###Canada
###Mexico
##Europe
###UK
###Germany
###France
###Spain
###Italy
###Rest of Europe
##Asia-Pacific
###China
###Japan
###India
###Australia
###South Korea
###Rest of Asia-Pacific
##LAMEA
###Brazil
###South Africa
###Saudi Arabia
### Rest of LAMEA

# KEY MARKET PLAYERS

## Abbott Laboratories
## AbbVie (Allergan Plc)
## Astellas Pharma Inc.
## Boehringer Ingelheim Pharma GmbH & Co. KG
## Eli Lilly and Company
## GlaxoSmithKline plc.
## Merck & Co., Inc. (Merck Sharp & Dohme Corp)
## Pfizer Inc.
## Sanofi
## Teva Pharmaceutical Industries Limited

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（組織細胞機能薬）の最新刊レポート

Allied Market Research 社の最新刊レポート

本レポートと同じKEY WORD（industry）の最新刊レポート

よくあるご質問

Allied Market Research社はどのような調査会社ですか?

アライドマーケットリサーチ（Allied Market Research）は世界の多様な市場に関する戦略や将来推計、成長/衰退予測、機会分析、消費者調査などを行い、市場調査レポートを積極的に出版しています。もっと見る

調査レポートの納品までの日数はどの程度ですか?

在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。

注文の手続きはどのようになっていますか?

1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。

お支払方法の方法はどのようになっていますか?

納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。

データリソース社はどのような会社ですか?

当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。

前立腺肥大症治療薬市場：治療薬クラス（αブロッカー、5-αリダクターゼ阻害剤、ホスホジエステラーゼ-5阻害剤、その他）、治療タイプ（単剤療法、併用療法）別。世界の機会分析および産業予測、2021-2030年

サマリー

目次

Summary

Table of Contents

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

本レポートと同分野（組織細胞機能薬）の最新刊レポート

Allied Market Research 社の最新刊レポート

本レポートと同じKEY WORD（industry）の最新刊レポート

よくあるご質問

Allied Market Research社はどのような調査会社ですか?

調査レポートの納品までの日数はどの程度ですか?

注文の手続きはどのようになっていますか?

お支払方法の方法はどのようになっていますか?

データリソース社はどのような会社ですか?